Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Vanderbilt-Ingram Cancer Center
Mayo Clinic